Management of severely dilated pulmonary artery (PA) associated with severe pulmonary hypertension from congenital heart disease remains controversial, primarily due to its rare nature and concern for perioperative unpredictable complications. Herein, we report a 25 year-old female with a severely dilated PA (up to 73 mm), who was successfully treated by a PA graft replacement by creating a Y-shaped conduit using a 28 mm hemashield tube in the main PA and a 20 mm hemashield tube in both proximal parts of the branch PA. (Korean Circ J 2017;47(1):136-140) KEY WORDS: Pulmonary arterial hypertension; Congenital heart defects; Pulmonary surgical procedure.
Introduction
Pulmonary artery (PA) dilatation associated with severe pulmonary hypertension is a rare condition. Despite its rarity however, unexpected deaths may result more frequently than commonly believed. 1)2) Possible mechanisms of sudden death include left main coronary artery (LMCA) compression by a markedly dilated PA and PA rupture or dissection with cardiac tamponade. 3) There has been no standard treatment guideline for a dilated PA from severe pulmonary hypertension, as it is not only quite rare, but also associated with a challenging surgical treatment with concerns for perioperative unpredictable complications.
Herein, we report a 25-year-old female with a severely dilated PA (up to 73 mm) and severe pulmonary hypertension from complete atrioventricular septal defect (AVSD), who was successfully treated by a PA graft replacement using a Y-shaped conduit creation with a 28 mm hemashield tube in the main pulmonary artery (MPA) and a 20 mm hemashield tube in both proximal parts of the branch PA.
Case
A 20 year-old female patient was referred for further treatment of complete AVSD with a PA aneurysm associated with severe pulmonary hypertension. She was diagnosed as having a left isomerism with inferior vena cava (IVC) interruption, dextrocardia, complete AVSD with single atrium, ventricular septal defect, and bilateral superior vena cava (SVC). She was diagnosed at another hospital at 10 years old due to symptoms of dyspnea on exertion. Because she showed severe pulmonary hypertension at that time, she was diagnosed as being in an inoperable state at another hospital. After discharge from the hospital, she did not visit any hospital for 10 years. After entrance into the University at the age of 20, she visited another hospital to check her medical status. She was diagnosed again, was not to be operated on, and prescribed with oral furosemide and digoxin. She visited our hospital again to get a secondary opinion. When she visited our hospital, she complained of exercise intolerance (difficult to climb 2 floor stairs, NYHA class III). On examination, she showed a palpable systolic A chest radiograph showed cardiomegaly and a dilated main pulmonary trunk and proximal branch PA (Fig. 1A ). An echocardiogram revealed that an inlet VSD was closed by an aneurysm and there was another 5 mm apical muscular VSD. From the cardiac computed tomography (CT), the MPA was measured to be 73 mm on the axial plane at the level of aorticopulmonary window ( Fig. 2A, B) . A cardiac catheterization showed a mean PA pressure of 64 mmHg, a pulmonary vascular resistance (PVR) of 13.9 wood units at room air. The systemic arterial oxygen saturation (SaO 2 ) was measured to be 83% at room air. After oxygen (10 L/min) was supplied, the mean PA pressure was 60 mmHg, PVR was 8.3 Wood units and SaO 2 was measured to be 94% (Table 1) . For the concern of irreversible hypertensive change in the PA, the option to operate was conceded and bosentan was started for 7 months to see the progression of PVR. After 7 months of bosentan treatment, cardiac catheterization revealed that the mean PA pressure dropped to 49 mmHg, and concomitantly PVR decreased to 10.2 Wood units and SaO 2 was measured to be 87.2% at room air. After oxygen (10 L/min) was supplied, the mean PA pressure was 47 mmHg, PVR was 6.0 Wood units and SaO 2 was measured to be 96.8%. We continued to give bosentan for the palliative medication. After 3 years of bosentan treatment, she showed maximal oxygen consumption (VO 2 max) of 20.4 mL/kg/min and desaturated as 62% by pulse oximetry at peak exercise from the cardiopulmonary exercise test (Table 1) .
Despite medical treatment for 5 years, the patient complained of orthopnea and worsening dyspnea (NYHA class III), accompanied by a further dilated PA (up to 80 mm) by echocardiography. Because we had concerns about PA dissection and intravascular thrombosis of PA, we finally decided to operate, performing reduction of MPA and ASD closure with fenestration. The operation was carried out via a median sternotomy with the use of a cardiopulmonary bypass. We replaced the MPA and proximal branch PA with a Y-shaped graft by a creation neo-MPA trunk using a 28 mm hemashield vascular graft and neo-branch proximal PA using a 20 mm hemashield vascular graft. She also underwent concomitant open-heart surgery including an atrial patch partitioning with an 8 mm fenestration, repair of the mitral valve cleft, division of right-sided SVC and anastomosis to the right atrial auricle with 16 mm polytetrafluoroethylene graft interposition to increase oxygen saturation and division of the remnant bilateral ductal artery (Fig. 3) . The cardiopulmonary bypass time was 445 minutes and aortic clamping time was 110 minutes. Pathology of the resected PA specimen revealed a pulmonary aneurysm with myxoid degeneration of vascular wall (Fig. 4) . However, postoperative course was not smooth.
Due to persistent bleeding after the operation, the patient underwent a hematoma evacuation and bleeding control twice. Bleeding focus was at an anastomosis site between the native right PA and graft mainly due to size discrepancy. Because of an acute kidney injury associated with massive bleeding and vancomycininduced nephropathy, renal replacement therapy was required After discharge, she showed increased VO 2 max of 23.9 mL/kg/min and desaturated only down to 80% at peak exercise at 1 year after the operation. Follow-up cardiac catheterization was performed 14 months after operation; the mean PA pressure was dropped to 49 mmHg and PVR decreased to 6.4 Wood units and SaO 2 was measured to be 94% at room air ( Table 1 ). The postoperative chest radiograph and cardiac CT revealed a decreased size of the neo-MPA and proximal branch PA with the remaining aneurysm of the lobar PA (Fig. 1B and 2C, D) . She showed improvement of daily performance (could climb up to 12 floor stairs, NYHA class II) at her last visit, 22 months after postoperation.
Discussion
Herein, we reported a 25 year-old female with a severely dilated PA (up to 80 mm by echocardiography) successfully treated by a PA graft replacement thtough a creation of a Y-shaped conduit using a 28 mm hemashield tube in an MPA and 20 mm hemashield tube in both proximal parts of the branch PA. Although the postoperative course was not easy, the patient's daily performance and quality of life definitely improved.
More than half of PA aneurysm cases are associated with congenital heart disease, where the pulmonary circulation may have significant volume and pressure overload, most frequently with patent ductus arteriosus. Some authors described that progressive dilatation of PA is related to changes on the vessel wall, rather than hemodynamic changes such as PA pressure, especially in lowpressure giant PA aneurysms including connective tissue disorders. 4) According to Laplace's law, the larger the vessel radius, the larger the wall tension, regardless of PA pressure, any aneurysm would continue to enlarge, thinning the arterial wall, and subsequently rupture. PA aneurysm was defined as a pathologic dilatation of the PA to a diameter of at least 1.5-fold the normal diameter. One study proposed a cut-off of 48 mm in diameter of the PA aneurysm, which represented the risk of unexpected death. 5) Another study proposed the risk factor for a dissection or rupture as an absolute PA diameter and growth rate (>75 mm and growth rate >2 mm/year). 6) Various complications of PA aneurysms such as airway compression, thrombus formation, LMCA compression and PA dissection may lead to unexpected mortality in one third of the patient populations.
7)8) PA dissection occurred in 20%, more and is often associated with high intravascular pressure and longer duration of elevated PA pressure. 6) Chest pain in pulmonary hypertension may often be a consequence of worsening pulmonary hypertension, right ventricle hypertrophy and strain leading to demand ischemia. Chest pain is also caused by LMCA extrinsic compression due to a dilated PA. The occurrence of LMCA compression correlates with increased PA pressure and PA diameter.
1)8) Associated problems include exercise related chest pain, ventricular dysfunction, malignant arrhythmias due to myocardial ischemia and sudden death. 5) In one study, risk factors predisposing to LMCA compression in pulmonary hypertension were younger age, severe PA dilatation (>40 mm), and a PA trunk/aorta ratio >1.2 (normal: 1.0). The treatment of LMCA extrinsic compression is also known to be safe by percutaneous coronary intervention. 1) Intravascular thrombi could be formed within aneurysm secondary to stasis from swirled blood flow, and may break off and lodge distally, which can lead to fatal pulmonary embolism. So, it has been generally accepted that anticoagulant treatment is necessary to PA aneurysm, although it may be suspended in cases of hemoptysis, progressive PA growth and PA dissection.
Williams and colleagues described the first report of repair of PA aneurysms in 1971. 9) Thereafter, various treatments have been reported, including aneurysmorraphy and angioplasty. Graft replacement would obtain a better outcome reducing recurrent aneurysmal dilation although there is a risk of bleeding at the anastomosis site, like in our case.
In conclusion, we must pay special attention to such symptoms for patients with severe PA aneurysms. Moreover, surgical treatments could be considered as a palliative treatment for some patients with a severely dilated PA with pulmonary hypertension from a congenital heart anomaly. Palliative surgery could improve exercise capacity and delay the progression of the disease, in parallel with conventional pharmacologic treatments, especially for patients with a high risk of serious complications such as PA ruptures. 
